Visioneering Technologies Inc. (ASX:VTI) is an eye care company focused on reshaping the field of vision through innovation. VTI is a pioneer in myopia management, leveraging advanced engineering to deliver superior outcomes for both patients and practitioners. Among its notable products is the NaturalVue® (etafilcon A) Multifocal 1-Day Contact Lens, an extended depth of focus lens that has been regarded as a significant advancement in the eye care industry for more than 20 years.
Visioneering Technologies Inc (ASX: VTI)
- Home
- Visioneering Technologies Inc (ASX: VTI)
Here are the latest articles on Visioneering Technologies Inc (ASX: VTI)
Visioneering Technologies NaturalVue contact lenses slow myopia – Study
August 27, 2020
Our eyes are getting worse and worse, and scientists aren’t exactly sure of the reason why. Myopia has exploded in recent decades, especially in East Asia, with the loss in distance vision affecting as many as 90 per cent of students in China. Worldwide as many as 27 per cent of people are nearsighted, and
FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering
November 20, 2019
Medtech developer Visioneering Technologies (ASX: VTI) may soon have its NaturalVue Multifocal (NVMF) contact lenses re-classified by the FDA which has just approved the first contact lenses which slow the progression of nearsightedness. The FDA approval was given to CooperVision’s MiSight® 1 day contact lens which slows the progression of myopia specifically in children. The
Recent Articles
